statement
The 600mg continuous dosing group recorded an ACR20 value of 92.5%, demonstrating excellent efficacy in absolute terms.
A statement by report author. Statements are as reported by the cited publishers — not verified by DecisionGateway.
600mg 지속 투여군의 ACR20 값이 92.5%를 기록하여 절대적 수치 측면에서도 우수한 효능 입증
Discussion
Related claims
In the D2T RA Phase 2b Period 2 results, the 600mg continuous dosing group achieved statistical significance (p-value), a surprise exceeding market expectations.report author · statementIMVT-1402 is the first clinical case to demonstrate that continuous high-dose dosing is possible without the hypercholesterolemia concerns seen with Batoclimab.report author · statement10mg의 섬유화 개선 유효성 입증 실패는 높은 중단율(11% vs. 3~4%)에 따른 생검 누락 때문으로 보이며, 약효 문제로 단정하기 어렵다.하나증권 · statementFollowing the D2T RA clinical success, the risk discount is reduced from 50% to 40%, leading to a revaluation of IMVT-1402.report author · statementCagriSema is injected subcutaneously once weekly.界面新闻 · statementImmunovant's Phase 2b trial of IMVT-1402 in difficult-to-treat rheumatoid arthritis (D2T RA) demonstrated excellent efficacy and safety, securing the validity of the development strategy.report author · statement